Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Recent & Breaking News (NDAQ:ARQL)

ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference

Business Wire June 17, 2019

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

Business Wire June 14, 2019

ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

Business Wire June 10, 2019

ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

Business Wire June 7, 2019

ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019

Business Wire May 30, 2019

ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

Business Wire May 15, 2019

ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019

Business Wire May 14, 2019

ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019

Business Wire May 8, 2019

ArQule Reports First Quarter 2019 Financial Results

Business Wire May 1, 2019

Sinovant Sciences Announces Approval of Derazantinib's Clinical Trial Application by the China National Medical Products Administration

Business Wire April 30, 2019

ArQule to Report First Quarter 2019 Financial Results on May 1, 2019

Business Wire April 17, 2019

ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019

Business Wire April 2, 2019

ArQule Announces Management Team Changes

Business Wire March 15, 2019

ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019

Business Wire March 13, 2019

ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019

Business Wire March 11, 2019

51 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  March 7, 2019

Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Benzinga.com  March 7, 2019

ArQule Reports Fourth Quarter and Full Year 2018 Financial Results

Business Wire March 7, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Benzinga.com  March 3, 2019

ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome

Business Wire February 25, 2019